Monoclonal antibody C242-PE conjugateAlternative Names: C242-PE; Monoclonal antibody C242-Pseudomonas exotoxin conjugate
Latest Information Update: 16 Dec 1996
At a glance
- Originator Nonindustrial source
- Developer Nonindustrial source; Pharmacia Corporation
- Class Immunotoxins; Monoclonal antibodies
- Mechanism of Action Protein synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Dec 1996 No-Development-Reported for Cancer in Sweden (Unknown route)
- 16 Dec 1996 No-Development-Reported for Cancer in USA (Unknown route)